Three traditional Chinese patent medicines combined with transarterial chemoembolization for primary liver cancer: A systematic review and Bayesian network meta-analysis.
- 1Department of Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
- 2Department of Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, China.
- 3Department of Medicine, Second Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Abstract
Background
To evaluate the objective response rate (ORR) and disease control rate of 3 Chinese herbal medicines (Compound Banmao Capsule, Huaier Granule, and Jinlong Capsule) combined with transarterial chemoembolization (TACE) for primary liver cancer using Bayesian network meta-analysis.Methods
We systematically searched randomized controlled trials (RCTs) across the Cochrane Library, Embase, PubMed, Web of Science, VIP Database for Chinese Technical Periodicals, China National Knowledge Infrastructure, and Wanfang databases from their inception to January 10, 2025. Two researchers independently screened the literature, extracted data, and assessed study quality using predefined inclusion and exclusion criteria. A Bayesian network meta-analysis was performed using RStudio to synthesize and hierarchically rank interventions by effect size in the included RCTs. This review was registered with PROSPERO (CRD420251019361).Results
Thirty-one RCTs involving 2604 patients with primary liver cancer were included. The network meta-analysis showed that, compared with TACE alone: Compound Banmao Capsule ranked highest for ORR (OR = 1.50, 95% CI: 1.08, 2.08), followed by Huaier Granule (OR = 1.47, 95% CI: 1.05, 2.05) and Jinlong Capsule (OR = 1.30, 95% CI: 1.02, 1.65). For disease control rate, the ranking was Compound Banmao Capsule (OR = 1.21, 95% CI: 0.76, 1.93), Jinlong Capsule (OR = 1.17, 95% CI: 0.85, 1.59), and Huaier Granule (OR = 1.12, 95% CI: 0.66, 1.91).Conclusion
For ORR, the combination of the 3 Chinese herbal medicines with TACE showed superior efficacy to TACE monotherapy, with Compound Banmao Capsule demonstrating the greatest therapeutic potential among the interventions evaluated.
Related
- Long-Term Outcomes of Interventional Treatments for Lung Cancer Liver Metastases: Transarterial Chemoembolization and Microwave Ablation
- Drug-eluting bead transarterial chemoembolization with immunotherapy and targeted therapy for advanced clear cell renal cell carcinoma: A case report.
- Case Report: Rapidly fatal hepatic portal venous gas following transarterial chemoembolization for hepatocellular carcinoma
- Enhanced Efficacy of Thalidomide‐Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi‐Center Cohort Study
- Lesion selection and external evaluation of clinical-imaging survival models after transarterial chemoembolization for hepatocellular carcinoma
BibTeX
@article{jiang2026three,
title = {{Three traditional Chinese patent medicines combined with transarterial chemoembolization for primary liver cancer: A systematic review and Bayesian network meta-analysis.}},
author = {Wei Jiang and Jun Luo and Chenguang Wu and Yan An and Yinzhong Dai and Junwei Shi and Chengying Lan and Jinfeng Qi and Shimei Hua and Huihui Liu},
journal = {Medicine},
year = {2026},
month = oct,
doi = {10.1097/md.0000000000051136},
url = {https://europepmc.org/article/MED/42888555},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Three traditional Chinese patent medicines combined with transarterial chemoembolization for primary liver cancer: A systematic review and Bayesian network meta-analysis.
AU - Wei Jiang
AU - Jun Luo
AU - Chenguang Wu
AU - Yan An
AU - Yinzhong Dai
AU - Junwei Shi
AU - Chengying Lan
AU - Jinfeng Qi
AU - Shimei Hua
AU - Huihui Liu
PY - 2026
DA - 2026/10/01
JO - Medicine
DO - 10.1097/md.0000000000051136
UR - https://europepmc.org/article/MED/42888555
AB - Background To evaluate the objective response rate (ORR) and disease control rate of 3 Chinese herbal medicines (Compound Banmao Capsule, Huaier Granule, and Jinlong Capsule) combined with transarterial chemoembolization (TACE) for primary liver cancer using Bayesian network meta-analysis.Methods We systematically searched randomized controlled trials (RCTs) across the Cochrane Library, Embase, PubMed, Web of Science, VIP Database for Chinese Technical Periodicals, China National Knowledge Infrastructure, and Wanfang databases from their inception to January 10, 2025. Two researchers independently screened the literature, extracted data, and assessed study quality using predefined inclusion and exclusion criteria. A Bayesian network meta-analysis was performed using RStudio to synthesize and hierarchically rank interventions by effect size in the included RCTs. This review was registered with PROSPERO (CRD420251019361).Results Thirty-one RCTs involving 2604 patients with primary liver cancer were included. The network meta-analysis showed that, compared with TACE alone: Compound Banmao Capsule ranked highest for ORR (OR = 1.50, 95% CI: 1.08, 2.08), followed by Huaier Granule (OR = 1.47, 95% CI: 1.05, 2.05) and Jinlong Capsule (OR = 1.30, 95% CI: 1.02, 1.65). For disease control rate, the ranking was Compound Banmao Capsule (OR = 1.21, 95% CI: 0.76, 1.93), Jinlong Capsule (OR = 1.17, 95% CI: 0.85, 1.59), and Huaier Granule (OR = 1.12, 95% CI: 0.66, 1.91).Conclusion For ORR, the combination of the 3 Chinese herbal medicines with TACE showed superior efficacy to TACE monotherapy, with Compound Banmao Capsule demonstrating the greatest therapeutic potential among the interventions evaluated.
SN - 0304-5412
SN - 1536-5964
ER -